

11-22-2004

Docket No.: P26,478-A USA

U.S. DEPARTMENT OF COMMERCE
United States Patent and Trademark Office



IT

To the Director of the United States Patent and Trademark Office

102886945

attached documents or the new address(es) below.

1. Name of conveying party(ies)/Execution Date(s):

Merrion Biopharma Limited (formerly known as
Adaptiv Biopharma Limited)

Execution Date(s): September 30, 2004

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance:

- ☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Government Interest Assignment
☐ Executive Order 9424, Confirmatory License
☐ Other

2. Name and address of receiving party(ies)

Name: Merrion Research I Limited

Internal Address: _____

(formerly known as Adaptiv Research I Limited)

Street Address: Unit 3015 Lake Drive

National Digital Park, Citywest

City: Dublin

State: _____

Country: IRELAND Zip: 24

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application or patent number(s):

☐ This document is being filed together with a new application.

A. Patent Application No.(s)

09/443,986

B. Patent No.(s)

Additional numbers attached? ☐ Yes ☒ No

5. Name and address to whom correspondence concerning document should be mailed:

Name: Marilou E. Watson

Internal Address: Synnstedt & Lechner LLP

Street Address: 2600 Aramark Tower

1101 Market Street

City: Philadelphia

State: PA Zip: 19107

Phone Number: 215-923-4466

Fax Number: 215-923-2189

Email Address: mwatson@synnlech.com

6. Total number of applications and patents involved:

1

7. Total fee (37 CFR 1.21(h) & 3.41) \$ 40.00

- ☒ Authorized to be charged by credit card
☐ Authorized to be charged to deposit account
☐ Enclosed
☐ None required (government interest not affecting title)

8. Payment Information

a. Credit Card Last 4 Numbers 1189

Expiration Date 07/06

b. Deposit Account Number _____

Authorized User Name _____

9. Signature:

Marilou E. Watson

Signature

11-16-2004

Date

Marilou E. Watson

Name of Person Signing

Total number of pages including cover

12

11/19/2004 00000148 09443986

01 FC:8021

Documents to be recorded (including cover sheet) should be faxed to (703) 306-5995, or mailed to:
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O. Box 1450, Alexandria, VA 22313-1450

ASSIGNMENT

THIS Assignment is effective as of the 30th day of September 2004, by and between **Merrion Biopharma Limited**, company registration number 368718 (formerly known as **Adaptiv Biopharma Limited**) a company incorporated under the laws of Ireland, having its registered office at 25-28 North Wall Quay, Dublin 1, Ireland (hereafter "Assignor") and **Merrion Research I Limited**, company registration number 385198 (formerly known as **Adaptiv Research I Limited**) a company incorporated under the laws of Ireland, having a place of business at Unit 3015 Lake Drive, National Digital Park, Citywest, Dublin 24, Ireland (hereafter "Assignee").

WHEREAS the Assignor is the proprietor of the patents and patent applications identified and set forth in the attached Schedule A (collectively, the "Intellectual Property"); and wishes to transfer the Intellectual Property to the Assignee.

WHEREAS on 11 August 2004 the Assignor changed its incorporated name from Adaptiv Biopharma Limited to Merrion Biopharma Limited and on 10 August 2004 the Assignee changed its incorporated name from Adaptiv Research I Limited to Merrion Research II Limited as set forth in the attached Schedule B.

WHEREAS the Assignee is desirous of acquiring the entire and exclusive right, title and interest in, to and under the Intellectual Property.

NOW, THEREFORE, In consideration of €100, receipt of which the Assignor hereby acknowledges, the Assignor, intending to be legally bound, does hereby sell, assign and transfer to the Assignee the entire right, title and interest in and to the Intellectual Property as may have been vested in the Assignor, including, but not limited to, the right to claim priority under statute, regulation, Treaty of the Paris Convention, and in all letters patent, including all continuations, divisions, continuations-in-part, reissues, extensions or reexaminations thereof, throughout the world, together with all claims for damages by reason of any past, present or future infringement or other unauthorized use of said Intellectual Property for Assignee's own use and enjoyment, and for the use and enjoyment of Assignee's successors, assigns or other legal representatives, to the end of the term for which the Intellectual Property is in effect, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment and sale had not been made.

Assignor authorizes and requests competent authorities in all countries to record Assignee as owner of the Intellectual Property, including any continuations, divisions, continuations-in-part, reissues, extensions or reexaminations thereof, and to issue any and all letters patent thereon to Assignee, as owner of the entire right, title and interest in, to and

under the same, for the sole use and enjoyment of Assignee, its successors, assigns or other legal representatives.

Assignor shall provide to Assignee, its successors, assigns or other legal representatives, cooperation and assistance at Assignee's request and expense (including the execution and delivery of any and all affidavits, declarations, oaths, exhibits, assignments, powers of attorney or other documentation as may be reasonably required) in the implementation or perfection of this Assignment.

This agreement shall be governed by and interpreted in accordance with the laws of Ireland and the parties hereby submit to the exclusive jurisdiction of the Irish courts.

This Assignment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

IN WITNESS of which the Assignor and Assignee have caused this Assignment to be signed and executed by the undersigned duly authorized officers.


MERRION BIOPHARMA LIMITED,
company number 368718

BY: 

NAME: John Lynch

TITLE: Managing Director


Before me personally appeared the above-named individual, to me known to be the person who is described in and who executed the foregoing Assignment and who acknowledged to me that he executed the same of his own free will for the purpose therein expressed.


Notary Public

(SEAL)

M-783358-1

2
Andrew F. Smyth
21, Clare Street,
Dublin 2, Ireland
Notary Public



PATENT
REEL: 015993 FRAME: 0182

MERRION RESEARCH I LIMITED,
company number 385198

BY: W Leonard

NAME: Thomas W. Leonard


TITLE: VP, CSO

Before me personally appeared the above-named individual, to me known to be the person who is described in and who executed the foregoing Assignment and who acknowledged to me that he executed the same of his own free will for the purpose therein expressed.

Andrew F. Smyth
Notary Public

(SEAL)

Andrew F. Smyth
21, Clare Street,
Dublin 2, Ireland.
Notary Public
Commissioned for Life



Schedule A

Patent Family Reference	Title	Status	Patent/ Application Numbers
1070	Composition and method for enhancing paracellular transport across cell layers (antisense occludin)	<u>Pending:</u> Europe PCT PCT	98/944189.4 WO 99/15649 PCT/IE98/00080
1071	Composition and method for enhancing transport across gastrointestinal tract cell layers (babassu oil)	<u>Pending:</u> Ireland	980809
1090	Solid oral dosage form containing an enhancer (C8-C10)	<u>Pending:</u> Europe	00/905186.3
1092	Enhanced delivery of nucleic acid based drugs	<u>Pending:</u> Europe PCT	00/927515.7 WO 00/67798
1093	Permeation enhancers - branched chains	<u>Pending:</u> PCT Europe	WO 02/092069 020731786.6
1094	Permeation enhancers - isostearic acid salts	<u>Pending:</u> Europe	020731787.4
1096	Delivery of a bioactive material (liquid)	<u>Pending:</u> PCT	PCT/IB02/03651

Patent Family Reference	Title	Status	Patent/ Application Numbers
1080	Method for inducing a cell-mediated immune response and proved parenteral vaccine formulations thereof	<u>Pending:</u> Europe PCT	99/940439.5 PCT/IE99/00087
1081	Oral vaccine compositions	<u>Pending:</u> Europe PCT	99/940438.7 PCT/IE99/00086
1060	Peptides which enhance transport across tissues and methods of Identifying and using the same	<u>Pending:</u> PCT <u>Issued:</u> Europe Ireland Ireland	PCT/IE96/00072 0859959 0859959 80466
1064	Retroinversion peptides that target GIT transport receptors and related methods	<u>Pending:</u> Europe PCT	99/972640.9 PCT/IE99/00117
1065	Membrane penetrating peptides	<u>Pending:</u> Europe PCT	00/968159.4 PCT/IB00/01491
1067	M-cell specific targeting ligands	<u>Pending:</u> PCT	PCT/IB02/03401
1826	Genetic analysis of M cells and methods and compositions targeting M cell receptors (ATLAS array)	<u>Pending:</u> PCT Europe	PCT/IB02/03866 02777590.7

Patent Family Reference	Title	Status	Patent/ Application Numbers
1004	Process and machine for automated manufacture of covered retard forms	<u>Pending:</u> United States	60/491157
1070	Composition and method for enhancing paracellular transport across cell layers (antisense occluding)	<u>Pending:</u> Canada Japan <u>Issued:</u> South Africa United States	2,304,313 2000-512941 98/8624 6,346,613
1071	Composition and method for enhancing transport across gastrointestinal tract cell layers (babassu oil)	<u>Issued:</u> United States	6,423,334
1090	Solid oral dosage form containing an enhancer (C8-C10)	<u>Pending:</u> Canada Japan United States	2,363,123 2000-600624 09/510,560
1092	Enhanced delivery of nucleic acid based drugs	<u>Pending:</u> Canada Japan United States	2,371,095 2000-616823 09/743,173
1093	Permeation enhancers – branched chains	<u>Pending:</u> United States PCT Canada Japan	10/145,194 PCT/US02/15210 2,446,619 020588986
1094	Permeation enhancers – isostearic acid salts	<u>Pending:</u> United States PCT Canada Japan	10/145,180 PCT/US02/15211 2,446,622 020588987

M-783358-1

Patent Family Reference	Title	Status	Patent/ Application Numbers
1096	Delivery of a bioactive material (liquid)	<u>Pending:</u> United States	60/302,540
1080	Method for inducing a cell-mediated immune response and proved parenteral vaccine formulations thereof	<u>Pending:</u> Canada Japan United States	2,341,358 2000-567237 09/386,266
1081	Oral vaccine compositions	<u>Pending:</u> Canada Japan United States	2,341,352 2000-567236 09/386,709
1060	Peptides which enhance transport across tissues and methods of Identifying and using the same	<u>Pending:</u> Canada Japan United States <u>Issued:</u> Austria Belgium Switzerland/Liechtenstein Germany Denmark Spain Finland France Great Britain Greece Italy Luxembourg Monaco Netherlands Portugal Sweden United States United States	2,235,226 518025/97 10/329,130 0859959 0859959 0859959 0859959 0859959 0859959 0859959 0859959 0859959 0859959 0859959 0859959 0859959 0859959 0859959 0859959 0859959 0859959 6,117,632 6,521,737
1060			

Patent Family Reference	Title	Status	Patent/ Application Numbers
1064	Retroinversion peptides that target GIT transport receptors and related methods	<u>Pending:</u> Canada Japan United States	2,349,290 2000-583950 09/443,986
1065	Membrane penetrating peptides	<u>Pending:</u> Canada Japan United States	2,386,231 2001-530372 09/671,089
1067	M-cell specific targeting ligands	<u>Pending:</u> United States	10/185,815
1826	Genetic analysis of M cells and methods and compositions targeting M cell receptors (ATLAS array)	<u>Pending:</u> PCT Canada United States	PCT/IB02/03866 2,443,644 10/116,275

Schedule B

The certificates of incorporation on change of name attached hereto.

Number 368718

Certificate of Incorporation on change of name

I hereby certify that

ADAPTIV BIOPHARMA LIMITED

having, by a Special Resolution of the Company,
and with the approval of the Minister for Enterprise,
Trade and Employment, changed its name, is now
incorporated as a limited company under the name

MERRION BIOPHARMA LIMITED

and I have entered such name on the Register accordingly.

Given under my hand at Dublin, this

Wednesday, the 11th day of August, 2004


for Registrar of Companies

Number 385198

Certificate of Incorporation on change of name

I hereby certify that

ADAPTIV RESEARCH I LIMITED


having, by a Special Resolution of the Company,
and with the approval of the Minister for Enterprise,
Trade and Employment, changed its name, is now
incorporated as a limited company under the name

MERRION RESEARCH I LIMITED

and I have entered such name on the Register accordingly.

Given under my hand at Dublin, this

Tuesday, the 10th day of August, 2004


for Registrar of Companies